| Title : Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions - Shen_2021_Fundam.Clin.Pharmacol_35_432 |
| Author(s) : Shen Y , Eades W , Yan B |
| Ref : Fundamental & Clinical Toxicology , 35 :432 , 2021 |
|
Abstract :
Remdesivir was recently approved to treat COVID-19. While this antiviral agent delivers clinical benefits, several safety concerns in many cases have been raised. This study reports that remdesivir at nanomolar concentrations inhibits carboxylesterase-2 (CES2) through covalent modifications. CES2 is a major drug-metabolizing enzyme. The combination of high potency with irreversible inhibition concludes that cautions must be exercised when remdesivir is used along with drugs hydrolyzed by CES2. |
| PubMedSearch : Shen_2021_Fundam.Clin.Pharmacol_35_432 |
| PubMedID: 33369768 |
| Gene_locus related to this paper: human-CES2 |
| Inhibitor | Remdesivir |
| Substrate | Remdesivir |
| Gene_locus | human-CES2 |
Shen Y, Eades W, Yan B (2021)
Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions
Fundamental & Clinical Toxicology
35 :432
Shen Y, Eades W, Yan B (2021)
Fundamental & Clinical Toxicology
35 :432